Scancell Ltd   Report issue

For profit Phase 1 Phase 2
Founded: Oxford United Kingdom (1997)

Organization Overview

First Clinical Trial
2010
NCT01138410
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Scancell Ltd

Active Ingredients

Drugs in Phase 2 Trials (2)

pembrolizumab (keytruda) (1 trial)

scib1 (2 trials)

Drugs in Phase 1 Trials (1)

covidity (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Melanoma (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 4
  • # of Trial APIs: 3